Observational Study to Evaluate Efficacy and Safety of Vidaslim®, a Medical Nutrition Therapy, for Weight Loss in Subjects with Obesity

Purpose: The study aimed to evaluate the effect of Vidaslim[R], meal replacement on weight, body mass index (BMI), waist circumference (WC), hip circumference (HC), and other cardiometabolic parameters and to see the impact of timing of Vidaslim meal replacement on the level of weight loss achieved. Methods: In a prospective, observational study, male and female subjects with obesity based on inclusion and exclusion criteria were administered Vidaslim (60 g in 200 mL water) once daily as a meal replacement (lunch or dinner) for 16 weeks. Results: A total of 107 subjects (mean age 34.09 [+ or -] 8.26 years) were included in the study. There was a significant reduction in weight by 13.4 kg (p=0.0001), BMI by 5.5 kg/[m.sup.2] (p=0.00001), WC by 3.7 inches (p=0.0001), and HC by 4.5 inches (p=0.0001) at the end of 16 weeks. Statistically significant reductions were noted in heart rate, fasting blood glucose, postprandial blood glucose, lipid profile (p=0.0001 for all), and systolic blood pressure (p=0.002) at 16 weeks. A significant change in hunger (p=0.0001), appetite (p=0.014), mood (p=0.021), sleep quality (p=0.0001), and general well-being (p=0.013) was observed at the end of 16 weeks. Replacing lunch or dinner with Vidaslim resulted in a significant reduction in weight (-9.8 kg versus -14.3 kg, respectively; p=0.0001 for both) compared to replacing breakfast (-3 kg, p=0.205) with Vidaslim over 16 weeks. No subject reported any side effects post-Vidaslim intervention. Conclusion: The medical nutrition therapy, Vidaslim, was found to be an effective and safe meal (lunch or dinner)-replacement strategy and brought a significant reduction in weight, WC, and HC over 16 weeks in overweight and obese individuals. Keywords: food supplement, overweight, anthropometric, cardiometabolic, meal replacement, blood glucose